The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
Adult
Aged
Azithromycin
/ administration & dosage
COVID-19
/ complications
Drug Combinations
Drug Therapy, Combination
Female
Hospitalization
/ statistics & numerical data
Humans
Hydroxychloroquine
/ administration & dosage
Iran
Length of Stay
Levofloxacin
/ administration & dosage
Lopinavir
/ administration & dosage
Male
Meropenem
/ administration & dosage
Middle Aged
Naproxen
/ administration & dosage
Oseltamivir
/ administration & dosage
Pneumonia, Viral
/ drug therapy
Prednisolone
/ administration & dosage
Retrospective Studies
Ritonavir
/ administration & dosage
Treatment Outcome
Vancomycin
/ administration & dosage
COVID-19 Drug Treatment
Combination therapy
Coronavirus disease 2019
Length of stay in hospitals (ALOS)
Journal
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
ISSN: 2008-2231
Titre abrégé: Daru
Pays: Switzerland
ID NLM: 101125969
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
27
03
2020
accepted:
02
06
2020
pubmed:
21
6
2020
medline:
15
12
2020
entrez:
21
6
2020
Statut:
ppublish
Résumé
There is no identified pharmacological therapy for COVID-19 patients, where potential therapeutic strategies are underway to determine effective therapy under such unprecedented pandemic. Therefore, combination therapies may have the potential of alleviating the patient's outcome. This study aimed at comparing the efficacy of two different combination regimens in improving outcomes of patients infected by novel coronavirus (COVID-19). This is a single centered, retrospective, observational study of 60 laboratory-confirmed COVID-19 positive inpatients (≥18 years old) at two wards of the Baqiyatallah Hospital, Tehran, Iran. Patient's data including clinical and laboratory parameters were recorded. According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir. The oxygen saturation (SpO2) and temperature were positively changed in patients receiving regimen I compared to regimen II (P = 0.013 and P = 0.012, respectively). The serum level of C-reactive protein (CRP) changed positively in group I (P < 0.001). Although there was a significant difference in platelets between both groups (75.44 vs 51.62, P < 0.001), their change did not clinically differ between two groups. The findings indicated a significant difference of the average length of stay in hospitals (ALOS) between two groups, where the patients under regimen I showed a shorter ALOS (6.97 vs 9.93, P = 0.001). This study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway. Graphical abstract.
Sections du résumé
BACKGROUND
BACKGROUND
There is no identified pharmacological therapy for COVID-19 patients, where potential therapeutic strategies are underway to determine effective therapy under such unprecedented pandemic. Therefore, combination therapies may have the potential of alleviating the patient's outcome. This study aimed at comparing the efficacy of two different combination regimens in improving outcomes of patients infected by novel coronavirus (COVID-19).
METHODS
METHODS
This is a single centered, retrospective, observational study of 60 laboratory-confirmed COVID-19 positive inpatients (≥18 years old) at two wards of the Baqiyatallah Hospital, Tehran, Iran. Patient's data including clinical and laboratory parameters were recorded. According to the drug regimen, the patients were divided into two groups; group I who received regimen I consisting azithromycin, prednisolone, naproxen, and lopinavir/ritonavir and group II who received regimen II including meropenem, levofloxacin, vancomycin, hydroxychloroquine, and oseltamivir.
RESULTS
RESULTS
The oxygen saturation (SpO2) and temperature were positively changed in patients receiving regimen I compared to regimen II (P = 0.013 and P = 0.012, respectively). The serum level of C-reactive protein (CRP) changed positively in group I (P < 0.001). Although there was a significant difference in platelets between both groups (75.44 vs 51.62, P < 0.001), their change did not clinically differ between two groups. The findings indicated a significant difference of the average length of stay in hospitals (ALOS) between two groups, where the patients under regimen I showed a shorter ALOS (6.97 vs 9.93, P = 0.001).
CONCLUSION
CONCLUSIONS
This study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway. Graphical abstract.
Identifiants
pubmed: 32562159
doi: 10.1007/s40199-020-00353-w
pii: 10.1007/s40199-020-00353-w
pmc: PMC7303568
doi:
Substances chimiques
Drug Combinations
0
lopinavir-ritonavir drug combination
0
Oseltamivir
20O93L6F9H
Lopinavir
2494G1JF75
Hydroxychloroquine
4QWG6N8QKH
Naproxen
57Y76R9ATQ
Levofloxacin
6GNT3Y5LMF
Vancomycin
6Q205EH1VU
Azithromycin
83905-01-5
Prednisolone
9PHQ9Y1OLM
Meropenem
FV9J3JU8B1
Ritonavir
O3J8G9O825
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
507-516Références
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
N Engl J Med. 2003 May 15;348(20):1986-94
pubmed: 12682352
J Infect Dis. 2004 Feb 15;189(4):648-51
pubmed: 14767818
Nat Med. 2007 Oct;13(10):1248-52
pubmed: 17891146
Daru. 2020 Dec;28(2):789-793
pubmed: 32385829
Lancet Infect Dis. 2013 Sep;13(9):752-61
pubmed: 23891402
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Biosci Trends. 2020 Mar 16;14(1):64-68
pubmed: 32037389
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
New Microbes New Infect. 2020 Apr 22;35:100684
pubmed: 32322397
Lancet. 2020 Feb 29;395(10225):683-684
pubmed: 32122468
J Infect. 2020 Jul;81(1):e13-e20
pubmed: 32283144
Therapie. 2020 Jul - Aug;75(4):355-362
pubmed: 32418728
Antimicrob Agents Chemother. 2013 May;57(5):2231-42
pubmed: 23459490
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Int J Infect Dis. 2020 May;94:74-77
pubmed: 32229257
Lancet Respir Med. 2020 Mar;8(3):e11-e12
pubmed: 32061335
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
Cytokine Growth Factor Rev. 2020 Jun;53:38-42
pubmed: 32360420
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
N Engl J Med. 2020 May 7;382(19):1851-1852
pubmed: 32187463
Pediatr Ann. 2014 Oct;43(10):417-20
pubmed: 25290132
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Stem Cell Rev Rep. 2020 Jun;16(3):427-433
pubmed: 32281052
Clin Immunol. 2020 May;214:108408
pubmed: 32247038
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Clin Infect Dis. 2003 Sep 15;37(6):857-9
pubmed: 12955652
Nat Med. 2020 Apr;26(4):465
pubmed: 32273604
HeartRhythm Case Rep. 2020 Apr 01;6(5):241-243
pubmed: 32363144
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
Leukemia. 2020 Jun;34(6):1503-1511
pubmed: 32372026
Chest. 2006 Jun;129(6):1441-52
pubmed: 16778260
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508